Published in Crit Care Med on April 01, 2001
Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med (2008) 2.93
In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood (2005) 1.99
Mechanical ventilation interacts with endotoxemia to induce extrapulmonary organ dysfunction. Crit Care (2006) 1.25
Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit Care (2006) 1.23
Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care (2008) 1.21
Genetic variation in the FAS gene and associations with acute lung injury. Am J Respir Crit Care Med (2010) 1.19
CD8+ T cells promote inflammation and apoptosis in the liver after sepsis: role of Fas-FasL. Am J Pathol (2007) 1.15
Molecular mechanisms underlying delayed apoptosis in neutrophils from multiple trauma patients with and without sepsis. Mol Med (2012) 0.94
Upregulation of the pro-apoptotic genes BID and FAS in septic shock patients. Crit Care (2010) 0.92
Mechanisms of immune resolution. Crit Care Med (2003) 0.85
Enhanced T-cell apoptosis in human septic shock is associated with alteration of the costimulatory pathway. Eur J Clin Microbiol Infect Dis (2009) 0.80
Association between lymphocyte expression of the apoptotic receptor Fas and pain in critically ill patients. J Pain Res (2017) 0.75
PATHOLOGICAL ASPECTS OF THE ANTI-INFLAMMATORY/IMMUNE SUPPRESSIVE RESPONSE IN SEPSIS AND SHOCK. Rec Res Dev Immunol (2003) 0.75
The Fas death pathway as a mechanism of multiple organ dysfunction syndrome: not so fast. Crit Care Med (2001) 0.75
Decoy Receptor 3 Improves Survival in Experimental Sepsis by Suppressing the Inflammatory Response and Lymphocyte Apoptosis. PLoS One (2015) 0.75
Effect of open heart surgery with cardiopulmonary bypass on peripheral blood lymphocyte apoptosis in children. Pediatr Cardiol (2008) 0.75
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 3.68
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol (2001) 1.91
Quantitative functional measures in MS: what is a reliable change? Neurology (2002) 1.81
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology (2008) 1.70
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology (2010) 1.67
Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology (2010) 1.63
Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology (2006) 1.57
Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology (2003) 1.44
A multiple sclerosis cluster associated with a small, north-central Illinois community. Arch Environ Health (2002) 1.41
ALS defeats gabapentin: reflections on another failed treatment. Neurology (2001) 1.41
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. Phys Ther (1994) 1.33
Prevalence of tics in schoolchildren and association with placement in special education. Neurology (2001) 1.32
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology (2005) 1.28
Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology (2005) 1.25
The behavioral spectrum of tic disorders: a community-based study. Neurology (2002) 1.23
Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord (1998) 1.20
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol (2000) 1.17
Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology (2001) 1.15
Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses (1999) 1.12
The measurement of ambulatory impairment in multiple sclerosis. Neurology (1997) 1.11
Quantitative assessment of motor fatigue and strength in MS. Neurology (1999) 1.08
Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology (1994) 1.06
Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol (1999) 1.06
Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? a review and a theoretical framework. Crit Care Med (2000) 1.05
Health care costs decline after successful epilepsy surgery. Neurology (2007) 1.04
Tourette's syndrome in a special education population: a pilot study involving a single school district. Neurology (1994) 1.03
Bilineal transmission in Tourette's syndrome families. Neurology (1994) 1.03
The VKIIIb light chain sub-subgroup: restricted association with mu heavy chain in normal human serum. Immunology (1985) 1.01
A randomized controlled trial of telephone peer support's influence on breastfeeding duration in adolescent mothers. Breastfeed Med (2010) 1.01
Alterations in cytokine and antibody production following chemical sympathectomy in two strains of mice. J Immunol (1995) 1.00
Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol (1996) 1.00
Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology (1998) 0.97
Enzymatic degradation of cyclic 2,3-diphosphoglycerate to 2,3-diphosphoglycerate in Methanobacterium thermoautotrophicum. Biochemistry (1992) 0.94
Predictability by somatic cell counts related to prevalence of intrammary infection within herds. J Dairy Sci (1982) 0.93
Sympathetic nervous system modulation of the immune system. III. Alterations in T and B cell proliferation and differentiation in vitro following chemical sympathectomy. J Neuroimmunol (1994) 0.92
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology (2000) 0.92
A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology (2002) 0.92
A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology (2001) 0.91
Similar immune response to nonlethal infection with herpes simplex virus-1 in sensitive (BALB/c) and resistant (C57BL/6) strains of mice. Cell Immunol (1994) 0.91
A presurgical psychosocial intervention for breast cancer patients. psychological distress and the immune response. J Psychosom Res (2000) 0.91
Moderate exercise is associated with enhanced antigen-specific cytokine, but not IgM antibody production in aged mice. Mech Ageing Dev (2001) 0.89
Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology (2001) 0.88
Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. Osteoarthritis Cartilage (2011) 0.88
Serum leptin levels are higher but are not independently associated with severity or mortality in the multiple organ dysfunction/systemic inflammatory response syndrome: a matched case control and a longitudinal study. Clin Endocrinol (Oxf) (2001) 0.88
Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile. Arch Neurol (2000) 0.87
Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology (1998) 0.87
Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. Ann Neurol (2000) 0.87
Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy. Qual Life Res (2006) 0.86
A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology (1997) 0.85
Exposure to conspecific alarm chemosignals alters immune responses in BALB/c mice. Brain Behav Immun (1993) 0.85
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology (1999) 0.85
A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology (1996) 0.83
A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord (1997) 0.83
Conditioned enhancement of antibody production using antigen as the unconditioned stimulus. Brain Behav Immun (1993) 0.83
The prevalence of PD in a nutritionally deficient rural population in China. Acta Neurol Scand (2005) 0.83
Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr (1996) 0.82
The role of the sympathetic nervous system in the modulation of immune responses. Adv Pharmacol (1998) 0.82
Higher-moment approaches to approximate interval estimation for a certain intraclass correlation coefficient. Stat Med (1999) 0.82
Heart rate, neuroendocrine, and immunological reactivity in response to an acute laboratory stressor. Psychosom Med (2001) 0.81
Effects of differential housing on the primary and secondary antibody responses of male C57BL/6 and BALB/c mice. Brain Behav Immun (1993) 0.81
Chemical sympathectomy increases numbers of inflammatory cells in the peritoneum early in murine listeriosis. Brain Behav Immun (2002) 0.81
Sympathetic nervous system modulation of tumor metastases and host defense mechanisms. J Neuroimmunol (1992) 0.81
Non-obscene complex socially inappropriate behavior in Tourette's syndrome. J Neuropsychiatry Clin Neurosci (1996) 0.81
Prolonged exercise suppresses antigen-specific cytokine response to upper respiratory infection. J Appl Physiol (1985) (2001) 0.81
The systemic inflammatory response, sepsis, and multiple organ dysfunction: new definitions for an old problem. Crit Care Nurs Clin North Am (1994) 0.80
Selecting a generic measure of health-related quality of life for use among older adults. A comparison of candidate instruments. Eval Health Prof (1998) 0.80
Depression, medical illness, and interleukin-1beta in older cardiac patients. Int J Psychiatry Med (2001) 0.80
Humor won, humor too: a model to incorporate humor into the healthcare setting (revised) Nurs Forum (1994) 0.80
Sympathectomy-induced immune changes are not abrogated by the glucocorticoid receptor blocker RU-486. Brain Behav Immun (1998) 0.80
The V kappa IIIb light chain sub-subgroup. II. Isotype expression in acquired hypogammaglobulinaemia and as a function of age. Immunology (1986) 0.80
The role of multifamily therapy in promoting retention in treatment of alcohol and cocaine dependence. Am J Addict (1998) 0.79
Decreased herpes simplex viral immunity and enhanced pathogenesis following stressor administration in mice. J Neuroimmunol (1992) 0.79
Voluntary consumption of cyclophosphamide by Mrl mice. Brain Behav Immun (1989) 0.79
Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia. Arch Pediatr Adolesc Med (1999) 0.79
The effects of exposure to dietary nickel and zinc upon humoral and cellular immunity in SJL mice. J Neuroimmunol (1991) 0.78
Chemical sympathectomy alters numbers of splenic and peritoneal leukocytes. Brain Behav Immun (2002) 0.78
Chemical sympathectomy increases the innate immune response and decreases the specific immune response in the spleen to infection with Listeria monocytogenes. J Neuroimmunol (2001) 0.78
Stressor-induced alterations in immune response and viral clearance following infection with herpes simplex virus-type 1 in BALB/c and C57B1/6 mice. Brain Behav Immun (1997) 0.78
Voluntary consumption of cyclophosphamide by nondeprived Mrl-lpr/lpr and Mrl +/+ mice. Pharmacol Biochem Behav (1990) 0.78
Psychosocial influences on immune responses to HSV-1 infection in BALB/c mice. Brain Behav Immun (1997) 0.77
A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol (1993) 0.77
Pavlovian conditioning of the immune system. Int Arch Allergy Immunol (1994) 0.76
An educational model for the acute care nurse practitioner. Crit Care Nurs Clin North Am (1995) 0.76
Cost benefit analysis of lactation therapy with somatic cell counts as indications for treatment. J Dairy Sci (1983) 0.76
Splenic norepinephrine is decreased in MRL-lpr/lpr mice. Brain Behav Immun (1993) 0.76
The use of bolus normal saline instillations in artificial airways: is it useful or necessary? Heart Lung (1985) 0.76
Thoracic disease in children with AIDS. Radiographics (1996) 0.75
CO2 anesthesia facilitates a serum antibody response to orally-administered antigens. Life Sci (1994) 0.75
Evaluation by enzyme-linked immunosorbent assay of local and systemic production of milk immunoglobulins to surface exopolysaccharide antigen in cows with staphylococcal mastitis. Cornell Vet (1987) 0.75